Tag: American Society of Clinical Oncology (ASCO)

Amgen’s Oncology Product AMG-510 Meeting An Unmet Need for Kras G12C Mutated Cancers

Amgen’s Oncology Product AMG-510 Meeting An Unmet Need for Kras G12C Mutated Cancers

Amgen's Outperforming After being boxed in, for the past couple of weeks, Amgen’s (AMGN) stock finally outperformed. The firm was outperforming silently with regard to its financial results, sciences, technologies, pipeline products and multiple newly approved products drugs.   In the News Amgen's Product AMG-510 Amgen announced new data from its ongoing Phase 1 study evaluating its unique cancer product AMG . . . This content …
The Nektar Good News Cannot be Hidden Any Longer

The Nektar Good News Cannot be Hidden Any Longer

Nektar Therapeutics We believe that Nektar Therapeutics (NKTR) is undervalued. We base this on the firm’s technological capability. Its current pipeline is filled with promising products. Today we learned that the U.S. FDA granted Nektar’s and Bristol-Myers Squibb’s . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

What Everyone Wants to Hear from ASCO The American Society of Clinical Oncology (ASCO) meeting is ongoing. What the oncologists, the analysts, the researchers and investors and other interested observers are anxious to hear this year is mostly about the improvements in the immune-oncology approaches. The Oncologists Want to Hear About: Up-to-date information from clinical trials on immunotherapies in order to practice the safest and …
Why Portola couldn’t flex its muscles or use them yet

Why Portola couldn’t flex its muscles or use them yet

All the buying and selling of Portola (PTLA) will not make any sense to us until the firm fulfills its obligations towards what is required by the authorities, by health care and by private third-party payers.  So, in the reporting of its Q2 financial results for the three months ending June 30, 2018, in addition to providing a corporate update, nothing matters really except knowing where the …
Good news, bad news & comebacks. Some ASCO results too

Good news, bad news & comebacks. Some ASCO results too

The Week in Review #23  ASCO  2018 - Small  publicly-­traded  oncology  biotech  firms,  large  oncology  biotech  firms,  and  giant  biopharmaceutical  firms,  in  addition  to  some  private  biotech  companies,  all  presented  results  and  observations  about  their  cancer  drugs  at  the  2018  American  Society  of  Clinical  Oncology  (ASCO)   meeting.  Most  presentations  were  useful,...
More promising news for Array from its melanoma combination clinical trial

More promising news for Array from its melanoma combination clinical trial

Array BioPharma (ARRY) announced updated results from the Phase 3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed that the median overall survival (mOS) was 33.6 months for patients treated with the combination of encorafenib and binimetinib compared to 16.9 months for patients treated with vemurafenib as a monotherapy. The combination reduced the risk of death compared to treatment with vemurafenib alone. The results, which was presented at the American Society …
About Nektar’s product NKTR- 214 at ASCO

About Nektar’s product NKTR- 214 at ASCO

The real news coming from the presentation at ASCO related to the combination of Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) was viewed as positive by many analysts and investor until a sell-side negative article led to an unwarranted giant selloff of the stock. Last Week Nektar Stock gained $10 dollars over news that the firm has already submitted a New Drug Application (NDA) to the FDA for NKTR-181, which is …
Prohost Letter #410

Prohost Letter #410

Prohost Letter #410 JUNE PDUFA DAYS This month, the FDA will decide on the approvals of drugs belonging to companies that Prohost has picked for investment. Usually, granting approvals rallies the stocks of the drugs’ developing firms. Sending Complete Response Letters for demands that might delay approvals would cut a substantial percentage of the stocks’ values, while rejections would cause the stocks to falter. Let’s …
Juno Also has Great News from Its CAR-T Cell Approach

Juno Also has Great News from Its CAR-T Cell Approach

Juno’s (JUNO) JCAR017 and JCAR014 are chimeric antigen receptor T cell (CAR-T) product candidates that target CD19, a protein expressed on the surface of almost all B cell malignancies. These malignancies include non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL). The clinical trial results of Juno’s CAR-T product JCAR017 in relapsed and refractory (r/r) aggressive B cell non-Hodgkin lymphoma (NHL) are …
Bluebird Flies Sky-High with Its CAR-T Wings

Bluebird Flies Sky-High with Its CAR-T Wings

AT ASCO CAR-T Was Created to Stay BlueBird Bio CAR-T Results Bluebird Bio (BLUE) presentation was well received at ASCO after the firm stated results demonstrating that all the 15 evaluable patients in the clinical trial of its chimeric antigen receptor T cell (CAR-T) drug “bb2121 responded to treatment. Data were convincing demonstrating 89% of the patients observed their tumors shrink with 27% seeing their …
Data From ASCO and Data from the Internet

Data From ASCO and Data from the Internet

As we wrote in Prohost Letter #409, a transformation in this year’s American Society of Clinical Oncology meeting (ASCO) is further elaborating on Checkpoint inhibition and chimeric antigen receptor T-cell (CAR-T) approaches’ limitations. Both are attempts towards making Immunotherapy for cancer a successful treatment. Checkpoint inhibitors have reached the market at the hands of Merck, Bristo-Myers Squibb and Roche, with other firms coming forward with products …
Prohost Letter #409

Prohost Letter #409

Prohost Letter #409 ASCO The American Society of Clinical Oncology (ASCO) meeting is around the corner. The Meeting, which will begin on Friday June 2, 2017 and will end on Monday 5, 2017 will be different than the past years for many reasons, including the following: -­ Checkpoint inhibition as Immunotherapy for cancer treatment moved from wishful thinking a decade ago, to promising cancer treatments …
Le CompaGnon Part 2

Le CompaGnon Part 2

Le CompaGnon Part 2 Wednesday June 22, 2016 From the  American Society of  Clinical  Oncology (ASCO)               Checkpoint inhibitors the CAR T Approach Adoptive cell therapy Oncolytic virus therapy Therapeutic vaccines Cytokines. Le CompaGnon Part 1 dealt with: - The two firms, MERK and BMY, who were the first to get approvals of their checkpoint inhibitors. These two . . . This content is for paid …
Le CompaGnon Part 1

Le CompaGnon Part 1

Le CompaGnon Part 1 TUESDAY June 14, 2016 The Eternal Market Games Unfortunately, the fabrication and misrepresentation of reality in media articles about member firms of the biotech sector succeeded in devastating promising companies having exceptional technologies and products. The damages went far beyond investors unwarranted losses. The damages were grave as to ruin of many firms. Indeed, many promising firms were forced to declare …
At ASCO: Exelixis Has Great News for Cobimetyx on RCC

At ASCO: Exelixis Has Great News for Cobimetyx on RCC

Additional data from pivotal METEOR trial underscore clinically meaningful benefit of Exelixis’ (EXEL) drug Cabometyx™ for patients with Advanced RCC AT the ASCO Meeting: ABSTRACT #4557, #4558 Cabometyx’™ benefit was robust and consistent regardless of prior treatment, location and extent of tumor metastases Positive data will be presented at the 2016 American Society of Clinical Oncology (ASCO) from subgroup analyses of the pivotal METEOR trial. …
Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

EXELIXIS AGAIN They said: Sell EXEL, as no partner is interested in the firm’s FDA approved cabozantinib to date. What really happened: It did not take long for IPSEN to come forward and take the responsibility of marketing cabozantinib abroad and pay $200 million upfront payment to Exelixis. They said: Although the FDA approved Cabometyx (cabozantinib) for advanced renal cell carcinoma (RCC), the drug will …
Exelixis Has Good News

Exelixis Has Good News

Exelixis Announces Positive Results from Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma - The results will be Presented at ASCO 2016 Genitourinary Cancers Symposium this month. - Data further highlight clinical benefit of cabozantinib across subgroups of patients with advanced renal cell carcinoma   - METEOR data are the foundation for the U.S. NDA filing submitted …
Prohost Letter #378 Part 2

Prohost Letter #378 Part 2

Prohost Letter #378 Part 2 2015 ASCO ANNUAL MEETING What a Big Revolution in Oncology! The ASCO meeting projected the huge advancement in the understanding, diagnosing and treating cancer. What looked as if a sudden explosion has brought in the big change, the change was, in fact a slow, deep-rooted evolution, built up over a long period of trial and error with the failures constituting …
A Company Report

A Company Report

VASCULAR BIOGENICS OPERATING AS VBL THERAPEUTICS Vascular Biogenics Ltd., operating as VBL Therapeutics (VBLT) is a late-stage clinical bio-pharmaceutical company focused on oncology and inflammatory diseases. Founded in 2000 and based in Tel Aviv, Israel, VBL’s has built its clinical pipeline based on two proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements: The proprietary Vascular Targeting System™ (VTS) platform technology, …